

Customer Number: 000959

DIVISIONAL-CONTINUATION APPLICATION TRANSMITTAL FORM
UNDER RULE 1.53(b) (former Rule 1.60)

DOCKET NUMBER	ANTICIPATED CLASSIFICATION OF THIS APPLICATION:		PRIOR APPLICATION SERIAL NUMBER: 08/175,158	PRIOR APPLICATION FILING DATE: DECEMBER 28, 1993
UVI-005CP2CN	CLASS:	SUBCLASS:	EXAMINER: G. BUGAISKY	ART UNIT: 1653

ASSISTANT COMMISSIONER FOR PATENTS
 BOX PATENT APPLICATION
 WASHINGTON, DC 20231

CERTIFICATION UNDER 37 CFR 1.10

Date of Deposit: November 15, 1999

Mailing Label Number: EL 373 306 687 US

I hereby certify that this 37 CFR 1.53(b) request and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Christian Almonte

Name of Person Mailing Paper

Signature of Person Mailing Paper

Dear Sir:

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR 1.53(b), of pending prior application serial no. 08/175,158 filed on December 28, 1993, of Walter D. Funk *et al.* entitled Recombinant Transferrins, Transferrin Half-Molecules and Mutants Thereof which is a continuation-in-part application of serial no. 07/832,029 filed February 6, 1992 which, in turn, is a continuation-in-part application of serial no. 07/652,869 filed February 8, 1991.

1. ☒ Enclosed is a copy of the latest inventor signed application, including the oath or declaration as originally filed. The copy of the enclosed papers is as follows:

- ☒ 31 page(s) of specification (including 9 pages of sequence listing)
☒ 4 page(s) of claims
☒ 1 page(s) of abstract
☒ 8 sheet(s) of informal drawings
☒ 15 page(s) of an *executed* declaration and power of attorney.

I hereby verify that the attached papers are a true copy of the prior complete application serial no. 08/175,168 filed on December 28, 1993.

2. ☒ Two verified statements to establish small entity status under 37 CFR 1.9 and 1.27, copies of which are enclosed, was filed in the prior application and such status is still proper and desired (37 CFR 1.28(a)).
 3. ☒ The filing fee is calculated below:

	NUMBER OF CLAIMS FILED			NUMBER EXTRA
TOTAL	* 26	MINUS	** 20	= 6
INDEP.	* 8	MINUS	*** 3	= 5
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS				

SMALL ENTITY	
RATE	FEE
x 9 =	\$ 54.00
x 39 =	\$ 195.00
+130 =	\$ 0.00
BASIC FEE	\$380.00
TOTAL	\$629.00

OR

OTHER THAN A SMALL ENTITY	
RATE	FEE
x 18 =	\$ 0.00
x 78 =	\$ 0.00
+ 260 =	\$ 0.00
BASIC FEE	\$ 0.00
TOTAL	\$ 0.00


OR

- Lahive & Cockfield, LLP
28 State Street
Boston, Massachusetts 02109

18. ☒ Pursuant to 37 CFR 1.821(e), the computer readable form of the sequence listing for this new application is to be identical with the computer readable form of application serial no. 08/175,158. Please use the computer readable form of application serial no. 08/175,158 in lieu of filing a duplicate computer readable form in this application. Pursuant to 37 CFR 1.821(f), the content of the paper copy of the sequence listing for this new application and the computer readable form of application serial no. 08/175,158 are the same.

Dated: **November 15, 1999**

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
Tel. (617) 227-7400


Giulio A. DeConti, Jr.
Registration No. 31,503
Attorney of Record

08/175,158

Applicant or Patentee: Walter D. Funk, et al. Attorney's
Serial or Patent No.: 08/175,158 C . No.: UVI-005CP2
Filed or Issued: December 28, 1993
Title: RECOMBINANT TRANSFERRINS, TRANSFERRIN HALF-MOLECULES AND
MUTANTS THEREOF

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(d)) - NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF NONPROFIT ORGANIZATION The University of British Columbia
ADDRESS OF NONPROFIT ORGANIZATION IRC331-2194 Health Science Mall, Vancouver, British Columbia,
CANADA V6T 1Z3
TYPE OF NONPROFIT ORGANIZATION
☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3))
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)
☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention entitled

RECOMBINANT TRANSFERRINS, TRANSFERRIN HALF-MOLECULES AND MUTANTS THEREOF

by inventor(s) Walter D. Funk, et al.
described in

- ☐ the specification filed herewith.
☐ application serial no. 08/175,158, filed December 28, 1993
☐ patent no. _____, issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME The University of Vermont and State Agricultural College
ADDRESS Burlington, Vermont 05405
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☒ NONPROFIT ORGANIZATION

NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Angus Livingstone
TITLE IN ORGANIZATION OF PERSON SIGNING Acting Director/University Industry Liaison Office
ADDRESS OF PERSON SIGNING IRC331-2194 Health Sciences Mall, Vancouver, B.C., CANADA V6T 1Z3

Angus Livingstone
SIGNATURE

FEB 15, 1994
DATE

Applicant or Patentee: Walter D. Funk, et al. Attorney's
Serial or Patent No.: 08/175,158 D No.: UVI-005CP2
Filed or Issued: December 28, 1993
Title: RECOMBINANT TRANSFERRINS, TRANSFERRIN HALF-MOLECULES AND
MUTANTS THEREOF

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(d)) - NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF NONPROFIT ORGANIZATION The University of Vermont and State Agricultural College
ADDRESS OF NONPROFIT ORGANIZATION Burlington, Vermont 05405
TYPE OF NONPROFIT ORGANIZATION
☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3))
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)
☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention entitled

RECOMBINANT TRANSFERRINS, TRANSFERRIN HALF-MOLECULES AND MUTANTS THEREOF

by inventor(s) Walter D. Funk, et al.

described in

- ☐ the specification filed herewith.
☐ application serial no. 08/175,158, filed December 28, 1993
☐ patent no. _____, issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)


NAME The University of British Columbia
ADDRESS IRC331-2194 Health Science Mall, Vancouver, British Columbia, CANADA V6T 1Z3
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☒ NONPROFIT ORGANIZATION

NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Regina H. White
TITLE IN ORGANIZATION OF PERSON SIGNING Director, Office of Sponsored Programs
ADDRESS OF PERSON SIGNING 340 Waterman Building, 85 So. Prospect St. Burlington, VT 05405


SIGNATURE

DATE

**RECOMBINANT TRANSFERRINS, TRANSFERRIN
HALF-MOLECULES AND MUTANTS THEREOF**

5

Related Applications

This application is a continuation-in-part of U.S. Application Serial Number
10 07/832,029 filed February 6, 1992, which is now pending and which is a continuation-in-
part of U.S. Application Serial Number 07/652,869 filed February 8, 1991, now
abandoned.

Government Support

15 The work leading to this invention was supported by one or more grants from the
United States Government.

Background of the Invention

The iron-binding pseudoglobulins collectively called transferrins or siderophilins
20 comprise a class of proteins with strikingly similar features. X-ray crystallographic
analyses of human lactoferrin (Anderson, B.F. *et al.* (1987) Proc. Natl. Acad. Sci. USA
84:1769-1773) and rabbit serum transferrin (Bailey, S. *et al.* (1988) Biochemistry
27:5804-5812) reveal that these proteins consist of two similar lobes connected by a short
bridging peptide and that each lobe contains two domains defining a deep cleft containing
25 the binding site for a metal ion and a synergistic anion.

The chicken ovotransferrin gene has been expressed in transgenic mice (McKnight,
G.S. *et al.* (1983) Cell (Cambridge, MA) 34:335-341) and a fusion protein of part of rat
transferrin with galactosidase has been expressed in *E. coli* (Aldred, A. *et al.* (1984)
Biochem. Biophys. Res. Commun. 122:960-965). Except for this fusion protein, attempts
30 to express transferrin or portions of the molecule in prokaryotic systems have been
unsuccessful (Aldred, A. *et al.* (1984) Biochem. Biophys. Res. Commun. 122:960-965).
The highly convoluted structure of the protein and large number of disulfide bridges in the
molecule are probably the major impediments to expression in bacterial hosts. Attempts
to mimic partially the natural protein folding environment by targeting the protein for
35 bacterial membrane transport via an attached alkaline phosphatase signal sequence have
been unsuccessful.

Summary of the Invention

This invention pertains to recombinant transferrin, to recombinant transferrins that bind to the transferrin receptor, to recombinant transferrin half- molecules comprising at least the metal-binding domains of a single lobe (amino-terminal or carboxy-terminal) of transferrin and to stable cell culture system for expression of the transferrin. The recombinant transferrin can be expressed in stable, transformed eukaryotic cells, such as baby hamster kidney cells, to yield essentially homogeneous (monodisperse) preparations of the full or half-molecule forms. The invention also pertains to mutant transferrins, non-glycosylated transferrins and transferrin half-molecules which have metal-binding or other properties which are different from the natural (wild-type) form of the transferrin. These include mutant transferrins and transferrin half-molecules which bind iron or other metals more or less avidly than natural transferrin.

Transferrin half-molecules can be used in metal chelation therapy to treat individuals affected with abnormalities of metal regulation or with metal poisoning. For example, transferrin half-molecules, especially mutant forms which bind iron with a higher avidity than natural transferrin, can be administered to iron-overloaded individuals, e.g., thalassemics, in order to clear excess toxic iron from their bodies. In addition, half-molecules, or mutants thereof having altered metal ion selectivities, could be used to clear other toxic metals, e.g., lead, mercury, cadmium, copper and zinc from the body.

Description of the Figures

Figure 1 shows construction of the hTF/2N expression vector in pNUT. A 2.3-kb cDNA encoding human serum transferrin was isolated from a human liver cDNA library and a 1.5-kb PstI/HaI fragment containing the complete amino-terminal domain coding sequence was cloned into M13mp18. Double translational stop codons and a HindIII recognition sequence were introduced by site-directed mutagenesis, allowing the isolation of a BamHI/HindIII fragment which, when joined to a BamHI/HpaII fragment, encodes the amino-terminal domain and signal sequence. This fragment was cloned into the eukaryotic expression vector pNUT, giving the vector pNUT-hTF/N2. In this plasmid, the transferrin cDNA is under the control of the metallothionein promoter (MT-1 pro) and the human growth hormone transcription termination signals (hGH3'); pNUT also contains the SV40 early promoter (SV40) driving expression of a resistant DHFR cDNA (DHFR cDNA) using transcription termination signals from human hepatitis B virus (HBV).

Figure 2 shows a Western blot of immuno- precipitates from various baby hamster kidney cell lines. Samples of cell lysates (a) and medium (b) from Zn-induced cell cultures were precipitated with anti-hTF antiserum. Samples of the resuspended pellets were analyzed by NaDodSO₄-PAGE, transferred to nitrocellulose and developed with anti-hTF antiserum followed by alkaline phosphatase conjugated anti-IgG. The hGH-pNUT and hTF/2N-pNUT transformed cell lines were selected in 500 μ M MTX and all

cell culture was performed in DMEM/10% fetal calf serum. Lane 1, BHK cells; lane 2, hGH-pNUT transfected BHK cells; lane 3, hTF/N2-pNUT transfected BHK cells. The positions of molecular weight markers ($\times 10^{-3}$) are indicated to the right of the blot, the position of the additional protein band of M_r 37,000 is also indicated (<37) to the right of the blot.

Figure 3 shows the isolation and PAGE analysis of hTF/2N. (Panel A) FPLC isolations on a column of Polyanion SI of recombinant hTF/2N (upper trace) and proteolytically derived hTF/2N (lower trace). (Panel B) NaDodSO₄-PAGE (5-12% gradient of acrylamide) of molecular weight standards (lane Mr) and 3 μ g of each of peaks a-d from panel A. (Panel C) Urea-PAGE under nonreducing conditions of the FPLC peaks a-d (recombinant hTF/2N species) and peaks e-h (proteolytically derived hTF/2N species) from panel A. The positions of the apo-protein (apo) and iron-bound protein (Fe) are indicated. The conditions used for FPLC are given under Materials and Methods. FPLC fractions were pooled as follows; peak a (fractions 23-27), peak b (28-31), peak c (32-38), peak d (39-45), peak e (28-31), peak f (32-36), peak g (38-44), and peak h (46-51).

Figure 4 shows titration of the major form recombinant hTF/2N with 10 mM Fe(III)(NTA)₂. The amount of protein was 3.68 A₂₈₀ units in 1.00 mL of 10 mM NaHCO₃. Visible spectra were run 5-10 minutes after each addition of iron to the magnetically stirred cuvette.

Figure 5 shows proton magnetic resonance spectra of recombinant hTF/2N. (a) Fourier transform spectrum with a line broadening of 2 Hz. (b) Convolution difference spectrum with a line broadening of 4 Hz and DC = 4.0, NS = 68,500. The protein sample was 8 mg in 0.1 mL of 0.1 M KCl in ²H₂O.

Figure 6 shows the ¹⁹F nuclear magnetic resonance spectrum of m-F-Tyr recombinant hTF/2N. The figure shows a Fourier transformation with a line broadening of 10 Hz, NS = 30,000. The protein sample was 6 mg in 0.1 mL of 0.1 M KCl in ²H₂O; the reference was 0.1 M trifluoroacetic acid in ²H₂O.

Figure 7 shows two separate oligonucleotides used as PCR primers to create the hTF/2C coding sequence. An *EcoRI* restriction fragment including coding sequence for the entire carboxy lobe was used as a template for 25 rounds of PCR amplification. Oligonucleotide 1 includes a *SmaI* recognition site and the natural hTF signal sequence at its 5' end and matches the coding sequence for amino acids 334 -341 of hTF at its 3' end. Oligonucleotide 2 matches sequence in the 3' untranslated region of the hTF cDNA and introduces a second *SmaI* recognition sequence at this site.

Figure 8 shows the construction of the hTf N413D/N611D expression vector in pNUT. Using a plasmid called pUC2-3 which contains the DNA coding region for the C-terminal lobe of hTf, each of the two mutagenic oligonucleotides described in Example V was used separately to introduce the desired mutations. The two resulting plasmids, Tf-

N413D and Tf-N611D, were cut with *AccI* and *StuI*; the DNA fragments containing the mutated residues were removed from agarose gel slices and ligated into the *AccI* site of a full-length Tf cDNA clone in pUC19 to give hTf(N/D). This plasmid was cleaved with *SacI* and *SphI*, the ends were made blunt, and the fragment was cloned into the *SmaI* site of pNUT to give pNUT-hTf(N/D). In this plasmid, the cDNA is under the control of the metallothionein promoter (MT) and the human growth hormone transcription termination signals (hGH). pNUT also contains the SV40 early promoter (SV40) driving expression of a mutated form of the dihydrofolate reductase (DHFR) cDNA using transcription termination signals from human hepatitis B virus (HBV).

Detailed Description of the Invention

This invention provides for the production of recombinant transferrin, recombinant transferrin half-molecules and mutant forms of full-length transferrin and transferrin half-molecules which have altered properties, such as improved metal-binding capability, compared to the natural transferrin molecules. Recombinant transferrins can be produced in large quantities and in substantially homogeneous (monodisperse) form. For example, recombinant half-molecules of human serum transferrin can be produced as an essentially homogeneous preparation substantially free of other human serum proteins. In contrast, half-molecules prepared by proteolysis of the holo-protein are difficult to purify and, in fact, the carboxy-terminal half of human transferrin cannot be satisfactorily prepared by proteolytic means. Recombinant techniques also allow the application of mutagenesis to design and produce new forms of transferrin.

In general, a recombinant transferrin of this invention is produced by transfecting a suitable host cell with a nucleic acid construct encoding the transferrin, culturing the transfected host cell under conditions appropriate for expression and recovering the recombinant transferrin expressed by the cell. The amino acid sequences for eight transferrins have been reported (See S.S. Baldwin Comp. Biochem Physiol. 106b: 203-218 (1993)). The DNA sequence (SEQ ID NO: 1) and amino acid sequence (SEQ ID NO: 2) for human serum transferrin has been determined (Yang, F. *et al.* (1984) Proc. Natl. Acad. Sci. USA 81:2752-2756). Full-length DNA for production of recombinant transferrins or truncated DNA encoding either the amino-terminal or carboxy-terminal lobe of transferrin or a portion thereof can be obtained from available sources or can be synthesized according to the known sequences by standard procedures. In order to provide for secretion of the recombinant transferrin into cell culture medium, DNA encoding a transferrin signal sequence (or other signal sequence suitable for the expression system) is positioned upstream of the transferrin encoding DNA.

Through receptor-mediated endocytosis, cell-surface transferrin receptors deliver transferrin with its bound iron to peripheral endosomes where the iron is released into the cell and then the iron-free transferrin or apotransferrin is recycled to the extracellular fluid.

Accordingly, another aspect of the invention is a homogenous preparation of human transferrin that is recognized by a transferrin receptor and is free of other human proteins.

Mutant forms of transferrin and transferrin half-molecules can be produced by standard techniques of site-directed mutagenesis. See Taylor *et al.* (1985) Nucleic Acids Res. **13**:8749-8764; Zoller, M.J. and Smith, M. (1983) Meth. Enzymol **100**:458-500. In particular, mutagenesis can be used to produce mutant transferrins which have metal-binding properties that are different from natural transferrin. For example, mutants capable of binding iron more avidly than natural transferrin can be produced. To produce such mutants, metal-binding domains can be mutagenized to replace one or more amino acids involved in binding with different amino acids. In human serum transferrin, the amino acids which are ligands for metal chelation are shown below (the number beside the amino acid indicates the position of the amino acid residue in the primary sequence where the first valine of the mature protein is designated position 1)

<u>Amino terminal lobe</u> <u>(amino acids 1-337)</u>		<u>Carboxy terminal lobe</u> <u>(amino acids 343-679)</u>	
Aspartic acid	63	Aspartic acid	392
Tyrosine	95	Tyrosine	426
Tyrosine	188	Tyrosine	517
Histidine	249	Histidine	584

In other types of transferrin, the numbering is different, but the ligands (amino acids) are the same.

Other regions of transferrin control binding and these too can be targeted for mutagenesis. These are usually positively charged amino acids such as lysine, histidine or arginine. For example, a mutant transferrin half-molecule which binds iron more avidly than natural transferrin can be produced by replacing the lysine residue at position 206 with glutamine (AAG→CAG) or by replacing the histidine residue at position 207 with glutamic acid (CAG→GAG).

Further, human serum transferrin contains two N-linked oligosaccharides at Asn-413 and Asn-611 corresponding to AAT and AAC, respectively. These glycosylation sites can be removed by changing the codons to GAT and GAC which correspond to aspartic acid using, for example, oligonucleotide-directed mutagenesis. Thus, a non-glycosylated transferrin can be produced recombinantly.

The transferrin-encoding DNA is cloned into a eukaryotic expression vector containing appropriate regulatory elements to direct expression of the DNA. A preferred eukaryotic expression vector is the plasmid pNUT described by Palmiter, R.D. *et al.* (1987) Cell **50**:435-443. This plasmid contains the mouse metallothionein promoter which induces transcription of the transferrin encoding DNA in the presence of heavy

metal and transcription termination signals of human growth hormone. In addition, pNUT contains dihydrofolate reductase gene under control of the SV40 early promoter with transcription termination signals from human hepatitis B virus to allow selection in cell culture. The gene encodes a mutant form of the enzyme which has a 270-fold lower
5 affinity for the competitive inhibitor methotrexate. This allows for the immediate selection of transfected cells in very high concentrations (0.5 mM) of methotrexate and abrogates the need for a recipient cell line that is deficient in dihydrofolate reductase. pNUT also contains pUC18 derived sequences which allows it to be amplified in *E. coli* to provide sufficient amounts of the plasmid for transfection of recipient cells.

10 The expression vector containing the DNA encoding the transferrin is incorporated into an appropriate host cell. The preferred host cell is a eukaryotic cell which can be transformed with the vector to yield a stable cell line which expresses a functionally active transferrin construct. A particularly useful cell is the baby hamster kidney cell. Baby hamster kidney cells can be transfected with a vector carrying the DNA construct
15 encoding a transferrin (such as the pNUT plasmid) to provide a stable cell culture system which expresses and secretes a functionally active transferrin (full or half-molecule). These cells are well-suited for economical, large scale growth and can be obtained from readily available sources.

Standard techniques, such as calcium phosphate coprecipitation or electroporation
20 can be used to transfect the eukaryotic host cell with the vector. The cell is then cultured under conditions appropriate to induce expression of the transferrin. For example, baby hamster kidney cells transfected with the pNUT vector are stimulated to express the transferrin construct in the presence of heavy metals. Baby hamster kidney cells are preferably cultured in the medium Dulbecco's Modified Eagle's medium-Ham's F-12
25 nutrient mixture with the serum substitute Ultrosor G™ (Gibco) at about 1%.

After an appropriate culture period, the expressed and secreted transferrin can be recovered from the culture medium. Standard purification procedures can be employed to yield a substantially homogeneous preparation of the recombinant transferrin. In one embodiment, the transferrin in the culture medium is saturated with iron and then purified
30 by anion exchange chromatography.

The recombinant transferrins of the invention can be used to chelate and clear iron or other toxic metals from the body. The customary approach to iron chelation *in vivo* has been to assess a wide variety of naturally-occurring siderophores of microbial origin and synthetic iron chelators for their physiological effects, primarily the ability to bind and
35 clear iron from the body. Many such compounds have been studied with varying abilities to clear iron and often with unacceptable side effects (Pitt, C.G. *et al.* (1979) J. Pharm. Exp. Therap. 208:12-18). As a result, the only iron chelator used for clearing excess iron from humans remains deferoxamine, a cyclic peptide from *Streptomyces pilosis*.

A preferred transferrin for iron chelation therapy is a mutant transferrin half-molecule which binds iron more avidly than natural transferrin. The use of a mutant half-molecule allows for more efficient chelation and removal of the metal. A particularly preferred mutant half-molecule is K206Q, described in the Exemplification below, which contains a glutamine rather than a lysine at position 206.

A transferrin half-molecule is advantageous because unlike the holo-proteins, it passes through the glomeruli of the kidney and is excreted in the urine, so that metal is not only chelated but also cleared from the body. Moreover, the single half-molecules do not bind to transferrin receptors on the membrane of tissue cells and therefore do not deliver iron to these tissues. Further, half-molecules of human transferrin would probably be recognized as "self" by the human body and therefore would not elicit an immunological response.

In addition, mutant half-molecules can be designed to have altered metal ion selectivities. The chelators could be used to clear other toxic metals from the body, e.g., lead, mercury, cadmium, and copper.

For chelation therapy, the recombinant transferrin is administered to a patient in amounts sufficient to chelate the metal and reduce circulating levels below toxic levels. Generally, it is administered in a physiologically acceptable vehicle, such as saline, by a parenteral route (typically intravenously).

Recombinant full-length human transferrin can be used in nonserum supplements or replacements for cell culture media. Transferrin is required for iron uptake by growing cells. The use of recombinant transferrin avoids the risk of contamination with, e.g., HIV or hepatitis virus associated with transferrin purified from human serum or prions from fetal bovine serum.

The invention is illustrated further by the following exemplification:

EXEMPLIFICATION

I. Production of Recombinant Transferrin Half- Molecule Comprising the Amino-Terminal Lobe.

5

MATERIALS

T4 DNA ligase, DNA polymerase I (Klenow fragment) and T4 polynucleotide kinase were purchased from Pharmacia-PL Biochemicals. Restriction endonucleases were purchased from Pharmacia-PL Biochemicals and Bethesda Research Laboratories.

10 Oligodeoxyribo- nucleotides were synthesized on an Applied Biosystems 380A DNA Synthesizer. Nitrocellulose filters were obtained from Schleicher and Schuell, ³²P-labeled nucleotides from New England Nuclear, goat anti-human transferrin antiserum from the Sigma Chemical Company, formalin-fixed *Staphylococcus aureus* cells from Bethesda Research Laboratories, the Protoblot immunoscreening detection system from
15 Promega, the oligonucleotide-directed mutagenesis kit from Amersham, Dulbecco's modified essential medium and fetal bovine serum from Gibco, and anti-human transferrin monoclonal antibody HTF-14 was from the Czechoslovakian Academy of Sciences. All other reagents were analytical grade or purer.

20 METHODS

Isolation of Human Serum Transferrin (hTF) cDNA. A human liver cDNA library constructed in the *E. coli* expression vector pKT-218 (Prochownik, E.V. *et al.* (1983) *J. Biol. Chem.* 258:8389-8394) provided by Dr. Stuart Orkin, (Harvard University) was screened using a synthetic oligonucleotide coding for the amino-terminal eight amino
25 acids of serum hTF as a hybridization probe. The oligonucleotide corresponded to nucleotides 88 to 111 of the hTF cDNA sequence reported by Yang, F. *et al.* (1984) *Proc. Natl. Acad. Sci. USA* 81:2752-2756). The oligonucleotide was end-labeled with T4 polynucleotide kinase and ³²P-ATP (Chaconas, G. and van de Sande, J.H. (1980) *Methods Enzymol.* 65:75-85), and used to screen approximately 10⁵ colonies. Restriction
30 endonuclease mapping of positive clones and DNA sequence analysis were performed by using standard procedures with pUC19 and M13mpl9 vectors, respectively (Maniatis, T. *et al.* (1982) *Molecular Cloning, a Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; Messing, J. (1983) *Methods Enzymol.* 101:20-78; Sanger, F. *et al.* (1977) *Proc. Natl. Acad. Sci. USA* 74:5463-5467).

35 **Expression Vector and Cell Culture.** The eukaryotic expression vector pNUT (Palmiter, R.D. *et al.* (1987) *Cell* (Cambridge, MA) 50:435-443) and baby hamster kidney (BHK) cells were provided by Dr. Richard D. Palmiter (Howard Hughes Medical Institute, University of Washington). After synthesis, oligonucleotides were purified on C₁₈ reverse-phase columns (Sep-Pak, Waters Associates; Atkinson, T. and Smith, M. (1984)

Oligonucleotide Synthesis: A Practical Approach (Gait, M.J., Ed.) pp 35-81, IRL Press, Oxford). Site-directed mutagenesis was performed by using the method of Taylor, J.W. *et al.* (1985) Nucleic Acids Res. 13:8749-8764). Plasmid DNA was prepared from *E. coli* JM105 and purified by two successive centrifugation steps with cesium chloride density gradients.

BHK cells were grown in Dulbecco's modified essential medium (DMEM) with 10% fetal bovine serum to approximately 10^7 cells per 10-cm dish and were subsequently transfected with 10 μ g of plasmid by the calcium phosphate co-precipitation technique described by Searle, P.F. *et al.* (1985) Mol. Cell. Biol. 5:1480-1489). After 24 hours, the medium was changed to DMEM containing 100 μ M methotrexate (MTX) and surviving cells were serially selected to 500 μ M MTX. In some experiments, cells were selected immediately with 500 μ M MTX. Large scale roller bottle cultures were initiated by seeding approximately 5×10^7 cells into each 850 cm² roller bottle containing 100 mL of DMEM-MTX. Cultures were induced at 80% confluency by the addition of ZnSO₄ to the medium to a final concentration of 0.08 mM. The medium was harvested 40 hours later.

Immune-precipitation and Western Blotting. Immune-precipitation of cell culture medium and cell lysates was performed by the method of Van Oost, B.A. *et al.* (1986) Biochem. Cell Biol. 64:699-705). Precipitates were analyzed by electrophoresis on 12% polyacrylamide gels in the presence of NaDodSO₄ (Laemmli, U.K. (1970) Nature (London) 227:680-685), followed by blotting onto a nitrocellulose membrane. The blot was incubated in PBS containing 0.1 mg/ml gelatin, then treated with goat anti-hTF antiserum (250-fold dilution in PBS), and finally developed with an alkaline phosphatase-conjugated, rabbit anti-goat IgG antibody according to the supplier's instructions.

Amino Acid Substitution. To incorporate 3-fluorotyrosine into the recombinant hTF/2N as a ¹⁹F NMR probe, the culture medium was supplemented with D,L-m-fluorotyrosine (Sigma Chemical Company) at 16% of the concentration of L-tyrosine in the medium. The cells grew as well on this medium as on the medium lacking D,L-m-fluorotyrosine.

Isolation of Recombinant hTF/2N. Harvested culture medium was made 0.01% in phenylmethylsulfonyl fluoride to inhibit proteases and sufficient Fe(III)(NTA)₂ was added to saturate all transferrin in the medium. After stirring at room temperature, the solution was dialyzed for 24 hours versus cold running tap water, and then for a few hours versus Milli-Q purified water. Concentrated Tris-HCl buffer, pH 8.4 was added to a final concentration of 5 mM, the preparation was centrifuged to remove any debris, and was loaded onto a column (2.5 x 80 cm) of DEAE-Sephacel (Pharmacia) equilibrated with 10 mM Tris-HCl buffer, pH 8.4.

The column was then eluted with a linear gradient of NaCl (0 to 0.3 M) in the same buffer. Fractions showing a pink color were analyzed by NaDodSO₄-PAGE, and fractions containing the recombinant protein (Mr 37,000) were pooled. Such fractions also

contained bovine transferrin and albumin resulting from the fetal calf serum in the tissue culture medium. After concentration of the pooled fractions to 5 mL on an Amicon PM-10 membrane, the protein was chromatographed on a column (2.5 x 90 cm) of Sephadex G-75 Superfine (Pharmacia-PL Biochemicals) equilibrated with 100 mM ammonium bicarbonate.

Sometimes, a second chromatographic step through this column was necessary to resolve completely the hTF/2N from the bovine proteins. At this stage, the A_{465}/A_{410} was usually < 1.0 , indicating the presence of a contaminating heme-protein (possibly hemopexin). The hTF/2N was finally purified to homogeneity by FPLC on a column (1 x 10 cm) of Polyanion SI (Pharmacia) using a linear gradient of NaCl (0 to 0.3 M) in 50 mM Tris-HCl, pH 8.0 over a period of an hour at a flow rate of 1 ml/min. Fractions of 1 mL were collected. Two to four protein bands emerged from the column, depending on the iron-binding status of the protein.

NaDodSO₄-PAGE was performed with 5% to 12% gradient gels and urea-PAGE was performed according to a modification (Brown-Mason, A. and Woodworth, R.C. (1984) J. Biol. Chem. 259:1866-1873) of the Makey, D.G. and Seal, U.S. (1976) Biochim. Biophys. Acta 453:250-256 procedure. Electrofocusing was performed on a 0% to 50% sucrose gradient in a 110 mL glass column (LKB) with 0.8% Pharmalyte, pH 5 to 8 (Pharmacia). The column was prefocused overnight to a final current of 2 mA at 1000 V.

The protein sample in 0.2 mL was diluted with 5 mL of solution withdrawn from the middle of the gradient. The sample was then reinjected into the isodense region of the column and focusing was continued for 24 hours. The gradient was collected from the bottom of the column in 1.5 mL fractions. Individual fractions were analyzed for A_{280} and for pH. Fractions with maximum A_{280} were selected as representing the pIs of the apo- and iron-saturated proteins.

Iron was readily removed from the iron-protein by incubation in a buffer containing 1 mM NTA, 1 mM EDTA, 0.5 M sodium acetate, pH 4.9. The apo-protein was concentrated to a minimum volume on a Centricon 10 (Amicon), then diluted and reconcentrated twice with water and twice with 0.1 N KCl. The apo-protein had a tendency to precipitate in pure water, but redissolved readily in 0.1 M KCl. The apo-protein was made 10 mM in NaHCO₃ and titrated with a suitable concentration of Fe(NTA)₂ while monitoring the absorbance at 465 nm.

Quantitative Immunoassay of Recombinant hTF/2N. A competitive solid state immunoassay was used to assess the concentration of recombinant hTF/2N in the culture fluid and at various stages of the purification (Foster, W.B. *et al.* (1982) Thromb. Res. 28:649-661). Proteolytically-derived Fe-hTF/2N (Lineback-Zins, J. and Brew, K. (1980) J. Biol. Chem. 255:708-713) was radioiodinated (Fraker, P.J. and Speck, J.C., Jr. (1978) Biochem. Biophys. Res. Commun. 80:849-857) with Iodogen (Pierce Chemical Company) and used as the standard. The monoclonal anti-hTF antibody HTF-14 was used as the

probe (Bartek, J. *et al.* (1984) Folia Biol. (Prague) 30:137-140). This antibody recognizes only the amino-terminal lobe of hTF (Mason, A.B. *et al.* (1988) Br. J. Haematol. 68:392-393) and does not recognize bovine transferrin (Penhallow, R.C. *et al.* (1986) J. Cell. Physiol. 128:251-260).

5 **Amino-terminal Sequence Analysis.** The amino-terminal sequences of both the minor and major-forms of recombinant hTF/2N were determined on an Applied Biosystems 470A Protein Sequencer in the Given Analytical Facility at the University of Vermont.

10 **Periodic Acid-Schiff Stain.** The presence of oligosaccharides in the recombinant hTF/2N was determined by staining the protein with periodic acid-Schiff reagent (Fairbanks, G. *et al.* (1971) Biochemistry 10:2606-2617).

15 **Nuclear Magnetic Resonance Spectroscopy.** Proton and fluorine NMR spectra were obtained on the 5.872 Tesla Bruker WM NMR spectrometer in the Camille and Henry Dreyfus NMR Laboratory, Department of Chemistry, University of Vermont, operating in the Fourier transform mode with quadrature detection. An ^{19}F probe was provided by Dr. Christopher W. Allen of that department. For proton spectra, spectrometer settings were as described previously (Valcour, A.A. and Woodworth, R.C. (1987) Biochemistry 26:3120-3125). For ^{19}F spectra, the sweep width was 30,000 Hz, the acquisition time was 0.279 seconds, a receiver delay of 2.0 seconds intervened
20 between acquisition and pulse of 15.0 μs (90°) and the sample was at 303°K. ^{19}F chemical shifts are relative to 0.1M trifluoroacetic acid in $^2\text{H}_2\text{O}$. Protein samples were 6 to 8 mg in 0.1 mL of 99.8 atom% $^2\text{H}_2\text{O}$, and spectra were run on these samples in 0.1 mL capsules inserted into standard 5 mm NMR tubes containing $^2\text{H}_2\text{O}$. Free induction decays of ^{19}F spectra were subjected to a line-broadening of 10 Hz prior to Fourier
25 transformation.

RESULTS

30 **Isolation of Human TF cDNA.** Approximately 100,000 colonies of a human liver cDNA library (Prochownik, E.V. *et al.* (1983) J. Biol. Chem. 258:8389-8394) were screened by using a 24 base oligonucleotide to the 5' sequence of the human TF cDNA as a hybridization probe. A single positive colony was obtained. Extensive restriction enzyme mapping of the plasmid isolated from this clone agreed completely with the patterns predicted from the human TF cDNA isolated from the same library by Yang, F. *et al.* (1984) Proc. Natl. Acad. Sci. USA 81:2752-2756. DNA sequence analysis of the 5'-
35 and 3'-termini of this clone confirmed that it was identical to the full-length clone isolated by Yang *et al.* All subsequent sequence analysis performed during the mutagenesis and subcloning of this cDNA conformed exactly to the sequence reported previously.

Vector Construction and Expression. Two translational stop codons and a unique *Hind*III recognition site were introduced into the linker region between the amino-

and carboxy-terminal domains of the hTF cDNA sequence by oligonucleotide-directed mutagenesis. The predicted translation sequence from this construct ends at Asp-337, according to the serum hTF numbering sequence (MacGillivray, R.T.A. *et al.* (1983) J. Biol. Chem. 258:3543-3553).

5 The expression vector pNUT (Palmiter, R.D. *et al.* (1987) Cell (Cambridge, MA) 50:435-443) contains a mouse metallothionein-1/human growth hormone gene fusion that has been shown to direct high levels of human growth hormone in transgenic mice (Palmiter, R.D. *et al.* (1983) Science (Washington, D.C.) 222:809-814). Important functional features of this vector include a mouse metallothionein-1 promoter to induce
10 cDNA transcription in the presence of heavy metals, pUC18 sequences to allow replication and selection in *E. coli*, and a dihydrofolate reductase (DHFR) cDNA driven by the SV40 early promoter to allow selection in cell culture. The DHFR cDNA encodes a mutant form of the enzyme which has a 270-fold lower affinity for the competitive inhibitor methotrexate (MTX) (Simonsen, C.C. and Levinson, A.D. (1983) Proc. Natl. Acad. Sci. USA 80:2495-2499). This allows for the immediate selection of transfected
15 cells in very high concentrations (0.5 mM) of MTX and abrogates the need for a recipient cell line that is deficient in DHFR.

To construct the expression vector pNUT-hTF/2N, the *Bam*HI-*Hind*III fragment from the bacterial expression vector was isolated (Figure 1). An *Hpa*II-*Bam*HI fragment
20 from the original transferrin cDNA clone was also isolated (Figure 1). These two fragments were then ligated into M13mpl8 replicative form DNA that had been cut with *Acc*I and *Hind*III. Replicative form DNA from the resulting M13 phage was isolated, the insert released by cleavage with *Xba*I and *Hind*III, and the ends made blunt ended. These steps ensured that the fragment included the translational stop signals, retained the natural
25 signal sequence for the protein, and was free of the dG/dC tail found in the original vector (Figure 1). This fragment was inserted into *Sma*I-cut pNUT, thus replacing the human growth hormone gene with a hTF/2N encoding cDNA, but leaving the transcriptional termination signal from the growth hormone gene intact. This plasmid was transfected into BHK cells and the resulting transformants were selected in the presence of MTX.

30 To analyze the mRNA transcripts produced by the transfected BHK cells, total RNA was electrophoresed on an agarose gel in the presence of formaldehyde (Maniatis, T. *et al.* (1982) Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). After transfer to nitrocellulose, the blot was analyzed by using an oligonucleotide to the 3' untranslated region of the hGH gene as a hybridization probe.
35 An inducible mRNA of approximately 1.4 kb was detected in the transfected cell line but not in mock-infected BHK cells (data not shown). This agreed with the predicted size of the hTF/2N mRNA, including the expected hGH 3' untranslated sequence and poly (A) tail.

To analyze the polypeptides produced by the transformed BHK cells, Western blot

analysis was performed both on cell lysates and the medium of various cell lines (Figure 2). Samples of BHK cells, BHK cells containing the hGH-pNUT plasmid, and BHK cells containing the hTF/2N-pNUT plasmid were grown in DMEM (BHK cells) or DMEM-MTX (BHK cells containing pNUT vectors). When the cells were reaching confluence, samples of medium were taken and cell lysates were prepared. These samples were incubated successively with goat anti-hTF antiserum and formalin-fixed *S. aureus* cells (Van Oost, B.A. *et al.* (1986) *Biochem. Cell Biol.* 64:699-705).

Bound proteins were eluted by incubation with NaDodSO₄, electrophoresed on a polyacrylamide gel, and transferred to a nitrocellulose membrane. The membrane was then incubated with goat anti-hTF antiserum and rabbit anti-goat immunoglobulin conjugated to alkaline phosphatase. When cell lysates or medium from BHK cells (Figure 2, lanes 1a and 1b) or BHK cells with hGH-pNUT plasmid (Figure 2, lanes 2a and 2b) were analyzed, only the expected goat immunoglobulin bands (Mr 25,000 and 50,000) from the original goat anti-hTF antibodies and a small amount of cross-reacting material were observed. However, an additional band of Mr 37,000 was observed in cell lysates (Figure 2, lane 3a) or medium (Figure 2, lane 3b) of the BHK cells containing the hTF/2N-pNUT plasmid. The molecular weight of this polypeptide chain is in excellent agreement with the molecular weight of the hTF/2N molecule (37,833) calculated from the amino acid sequence.

The homogeneity of the hTF/2N product indicates the successful removal of signal sequence as cell lysate and secreted samples comigrate on SDS-PAGE. The anti-serum appears to be highly specific for human TF species, since little bovine TF is apparent in the precipitates.

In large scale cultures of the hTF/2N cell line grown in roller-bottles, the concentration of hTF/2N in the medium was approximately 10-15 µg/ml as detected by radioimmunoassay.

Isolation and Characterization of Recombinant hTF/2N. Recombinant hTF/2N was purified by a three-step procedure that led routinely to an 80% yield of the major form of the protein, based on radioimmunoassay. The final purification on Polyanion SI led to quantitative resolution of the apo- and iron-saturated forms of both the minor (<5%) and major constituents of the protein (Figure 3, panel A), as corroborated by urea-PAGE (Figure 3, panel C). Note that on urea-PAGE the slowest moving bands are apo-hTF/2N and the faster moving bands are Fe-hTF/2N. SDS-PAGE gels (Figure 3, panel B) showed the major and minor forms of recombinant hTF/2N to be monodisperse, of equal molecular weight and the major component to be free of carbohydrate by PAS stain (data not shown).

In general these preparations appear to have better monodispersity than proteolytically derived hTF/2N (Lineback-Zins, J. and Brew, K. (1980) *J. Biol. Chem.* 255:708-713) (Figure 3). For example, the chromatographic peaks are more regular for the

former, and the number of bands on urea-PAGE is greater for the latter. Spectral ratios for the iron-saturated recombinant protein are typically $A_{280}/A_{465} = 21$ and $A_{465}/A_{410} = 1.38$, which compare favorably with values for pure diferric transferrin isolated from human plasma. Titration of 3.68 A_{280} units of the apo-protein with Fe(NTA)_2 yields a slope corresponding to an $E_{465}(\text{mM}) = 2.1$ and gives for the apo-protein $E_{280}(\text{mM}) = 38.8$ (Figure 4), both reasonable values for a half-transferrin molecule (Lineback-Zins, J. and Brew, K. (1980) *J. Biol. Chem.* 255:708-713; Zak, O. *et al.* (1983) *Biochim. Biophys. Acta* 742:490-495). The pI's for the apo- and Fe-hTF/2N were 6.5 and 5.4, respectively.

Amino-terminal sequence analysis of both the minor and major forms of recombinant hTF/2N gave results identical to those found (MacGillivray, R.T.A. *et al.* (1983) *J. Biol. Chem.* 258:3543-3553) for holo-hTF from serum (Table 1).

The proton NMR spectrum of the recombinant protein (Figure 5) is very similar to that for the proteolytically-derived hTF/2N (Valcour, A.A. and Woodworth, R.C. (1987) *Biochemistry* 26:3120-3125), but the resonance lines are sharper for the recombinant protein. The ^{19}F NMR spectrum of the protein derived from a cell culture grown on medium supplemented with m-F-tyrosine (Figure 6) shows four well-resolved resonances, two possibly having an unresolved shoulder.

Table 1

Amino-Terminal Sequence of Human Transferrin and of the Recombinant Human Transferrin Amino-Terminal Half-Molecule^a

Protein	Amino Acid Sequence	Reference
human serum transferrin	V-P-D-K-T-V-R-W-C-A-V-S-	MacGillivray <i>et al.</i> (1983) (SEQ ID NO:5)
recombinant hTF/2N (major) ^{b, c}	V-P-D-K-T-V-R-W-X-A-V-S-	this report (SEQ ID NO:6)
recombinant hTF/2N (minor) ^d	V-P-D-K-T-V-	this report (SEQ ID NO:7)

^aThe recombinant hTF/2N sequences were determined on an Applied Biosystems 470A protein sequencer. Approximately 200 pmol of each sample was analyzed. ^bTwelve sequencer cycles were analyzed. ^cNo residue was identified at cycle 9; however, cysteine residues were not modified prior to the analysis. ^dSix sequencer cycles were analyzed.

By using recombinant DNA technology, a hTF/2N molecule is produced that functions identically with the proteolytically derived species as judged by several independent criteria. This represents the first reported expression in a stable cell culture system of a functionally active form of this important iron transport protein.

5 The pNUT based hTF/2N construction described here produces high levels of recombinant protein without the need for a DHFR-deficient cell line or tedious resistance amplification procedures. BHK cells are well-suited for economical, large scale growth and we are currently examining their growth characteristics on micro-carrier supports in bioreactor vessels. By using either roller bottles or a fermentor with a capacity of several
10 liters, we can easily produce sufficient recombinant protein even for techniques such as NMR that traditionally have required a high concentration of protein.

The minor form of recombinant hTF/2N isolated on Polyanion SI migrates more slowly than the major form on urea-PAGE (Figure 3, panel C), but at the same rate on SDS-PAGE (Figure 3, panel B). Thus, the apparent molecular weights are the same but
15 the relative degrees of unfolding in 6 M urea differ. Note that the proteolytically-derived apo-hTF/2N shows even faster migrating species in 6 M urea (Figure 3, panel C, fractions g and h).

Contamination of apo-hTF/2N with Fe-hTF/2N and vice versa on these gels arises from the method of pooling FPLC fractions, from some loss of bound iron on the urea gel and from binding of contaminating iron during workup of the FPLC samples. Identical N-
20 terminal sequences (Table 1) show that the signal peptide has been removed from both minor and major forms of the recombinant protein. As in hTF/2N from human serum (Lineback-Zins, J. and Brew, K. (1980) *J. Biol. Chem.* 255:708-713), the recombinant hTF/2N is non-glycosylated. The cause of the difference between major and minor forms
25 of hTF/2N is unknown at present. The minor form has never represented more than 5% of the total recombinant protein and is usually less than 1%. Thus, the goal of isolating a monodisperse recombinant hTF/2N (the major form) has been achieved.

The iron binding behavior, pIs, migration on NaDodSO₄-PAGE and urea-PAGE and proton NMR spectra of the recombinant hTF/2N match reasonably well those of the
30 hTF/2N derived from amino terminal monoferric hTF by proteolysis with thermolysin (Lineback-Zins, J. and Brew, K. (1980) *J. Biol. Chem.* 255:708-713; Valcour, A.A. and Woodworth, R.C. (1987) *Biochemistry* 26:3120-3125), except as noted above. The major form of the recombinant protein shows a higher degree of monodispersity (Figure 3) and its proton NMR spectrum shows sharper resonance lines than does the proteolytically
35 derived hTF/2N. There has been insufficient minor form for analysis by NMR.

Previous studies of the incorporation of m-fluorotyrosine into alkaline phosphatase from *E. coli* have established the efficacy of ¹⁹F NMR for specifically probing the tyrosyl residues in a protein (Sykes, B.D. *et al.* (1974) *Proc. Natl. Acad. Sci. USA* 71:469-473; Hull, W.E. and Sykes, B.D. (1974) *Biochemistry* 13:3431-3437). Incorporation of m-F-

tyrosine into the recombinant hTF/2N proves that selective amino acid substitution is possible in this cell culture system and gives access to a specific NMR probe of tyrosyl side chains. This preparation behaves in all respects like the non-modified protein as described above for the non-substituted recombinant. When the cell culture conditions have been optimized to achieve higher levels of incorporation, changes in the ^{19}F NMR spectrum on addition of paramagnetic and diamagnetic metals and on changes in pH can be useful in studying the tyrosyl residues specifically involved in metal binding. Incorporation of selectively deuterated aromatic amino acids can allow dissection of the aromatic region of the proton NMR spectrum of the protein in similar fashion to the studies on lysozyme from Japanese quail (Brown-Mason, A. *et al.* (1981) J. Biol. Chem. 256:1506-1509).

II. Production of Recombinant Transferrin Half- Molecule Comprising Carboxy Terminal Lobe.

An *EcoRI* restriction fragment including the coding sequence for the carboxy lobe of hTF was isolated from the full length hTF cDNA and then used as a template for PCR-directed mutagenesis (Figure 2). Two oligonucleotides were synthesized to be used as PCR primers. Oligo 1 encodes a *SmaI* recognition site, followed by sequence encoding the natural signal sequence of hTF, followed by sequence matching the coding sequence for amino acids 334-341. The second oligonucleotide matches the complement of the 3' nontranslated region of the hTF cDNA and introduces a *SmaI* recognition sequence 3' to the normal translation termination site (nucleotides 2125-2127 using the numbering system of Yang, F. *et al.* (1984) Proc. Natl. Acad. Sci. USA 81:2752-2756). Twenty-five rounds of PCR amplification using Taq polymerase (Perkin Elmer) resulted in the desired DNA fragment which splices the natural signal sequence of hTF to the C lobe coding sequence. This fragment was then digested with *SmaI* and ligated with the large *SmaI* fragment of pNUT as for the hTF/2N expression studies.

III. Production of Recombinant Full Length Transferrin.

The coding sequence for human serum transferrin was assembled from restriction enzyme digestion fragments derived from the full-length cDNA clone isolated from a human liver library described above. Since the parental plasmid (pKT-218) of the original clone had a limited number of unique restriction enzyme recognition sites, a series of cloning steps was required to introduce the coding sequence into a convenient vector. This process was initiated by cloning a *HpaII/BamHI* fragment from the 5' end of the cDNA into the vector pUC 18 (Messing, J. (1983) Meth. Enzymol. 101:20-28). The resulting plasmid was digested with *BamHI* and *HindIII* and a *BamHI/HindIII* fragment

from the human transferrin cDNA was cloned adjacent to the initial fragment. The resulting plasmid was then digested with HindIII and PstI and a final HindIII/PstI fragment from the 3' end of the transferrin cDNA was cloned to complete the assembly of the full-length coding sequence. Digestion of the resulting plasmid with SacI and SphI released the full-length coding sequence as a single restriction fragment which was subsequently made blunt using T4 DNA polymerase and dNTPs and then cloned into the large SmaI fragment of pNUT (Palmiter *et al.* (1987) Cell 50:435-443) as described for the N- and C-terminal transferrin half-molecule coding sequences.

Plasmid DNA was prepared from *E. coli* JM105 and purified by two successive centrifugation steps with cesium chloride gradients. Baby hamster kidney (BHK) cells were grown in Dulbecco's Modified Eagles' medium-Ham's F-12 nutrient mixture (DMEM-F-12) (Gibco; Sigma) with 10% fetal bovine serum to approximately 10^7 cells per 100 mm dish and were subsequently transfected with 10 μ g of plasmid by the calcium phosphate coprecipitation technique described by Searle *et al.* (1985) Mol. Cell Biol. 5:1480-1489. After 24 hours, the medium was changed to DMEM-F-12 containing 500 μ M methotrexate to select the plasmid containing cells. Once selected, the cells were serially passaged at approximately 80% confluency with phosphate buffered saline containing EDTA (0.2 gm/l) to five 100-mm dishes, then to five T-175 flasks and finally to five expanded surface roller bottles (200 ml each). At the T-175 passage, a serum substitute, Ultrosor G (Gibco), at a level of 1% was used in place of fetal calf serum in DMEM-F-12 lacking phenol red.

It was found that once production levels were high (approximately 100 μ g/ml of medium), medium without Ultrosor G™ could sustain production of recombinant protein for at least two passages. This greatly simplified the isolation of the expressed full-length recombinant human serum transferrin. To isolate the recombinant protein, harvested culture medium is made 0.01% with respect to phenylmethanesulfonyl fluoride and sodium azide to inhibit proteases and bacterial growth respectively. Sufficient Fe^{3+} (nitrilotriacetic acid)₂ is added to saturate the transferrin present. The medium is reduced in volume to <10 ml and the transferrin is purified by passage over an anion exchange column (Polyanion SI, 1 x 10 cm) as described for the recombinant amino terminal human transferrin half-molecule above.

The isolated recombinant full-length human serum transferrin displays some heterogeneity on this column attributed to variation in the glycosylation pattern. The protein is monodisperse on NaDod SO₄-polyacrylamide gel electrophoresis and has a spectrum and spectral ratios which are comparable to purified human serum transferrin.

IV. Production of Mutant Transferrins.

Substitution mutants are designated using the conventional single letter amino acid symbol of the wild type (native) residue, followed by the positional number of the replacement in the primary sequence, (where valine of the mature protein is designated position 1) followed by the symbol for the replacement residue. For example, a mutant in which aspartic acid residue at position 63 is replaced by a serine residue would be designated D63S.

The production of hTF/2N mutants was accomplished by two techniques. A D63S substitution was prepared using the method of Nelson, R.M. and Long, G.L. (1989) Analyt. Biochem. 180:147-151. Briefly, a HpaII/BamHI fragment from the 5' end of the hTF/2N coding sequence was subcloned into pUC18 and then used as a template for a two step PCR-based mutagenesis procedure. The resulting DNA fragment was then recloned into M13mp18 and the sequence of the mutant construction was confirmed by dideoxy sequence analysis. The fragment was then released from the double stranded form of the sequencing vector by digestion with XbaI and BamHI and then ligated to a BamHI/HindIII fragment from the original hTF/2N construction to produce a full length D63S-hTF/2N coding sequence, the fidelity of this splicing was confirmed by restriction digestion analysis and was subsequently cloned into pNUT as before.

The substitution mutants G65R, D63C, K206Q and H207E were produced by subcloning the entire hTF/2N coding sequence into M13mp18, which was then used as a template for oligonucleotide-directed mutagenesis (Zoller, M.J. and Smith, M. (1983) Meth. Enzymol. 100:458-500) using the dut⁻, ung⁻ selection procedure (Kunkel, T.A. (1985) Proc. Natl. Acad. Sci. USA 82:488-492). Following mutagenesis, the entire coding sequence for the mutant sequences was confirmed by dideoxy sequence analysis using sequencing primers targeted along the length of the coding sequence at 250 bp intervals. The desired coding sequences were then released by restriction digestion, made blunt and inserted into pNUT as before.

pNUT plasmids have been constructed containing the cDNA a) for full-length human serum transferrin (hTF) and b) for various site-directed mutants of the amino-terminal half-molecule (hTF/2N). These mutants include 1) D63S patterned on the naturally occurring mutation found in the C-terminal half of human melanoferrin, b) G65R patterned on the naturally occurring mutant found in the C-terminal half of hTF from a patient in England, c) K206Q based on the wild type mutation in the C-terminal half of ovotransferrin (oTF) from hen's egg white, d) H207E based on the wild type mutation in human lactoferrin (hLTF) and e) D63C as an attempt to change the metal selectivity of the iron binding site. All of these constructions have been expressed in stable transformants of baby hamster kidney cells in 10 to 100 mg amounts of recombinant protein. In addition pNUT plasmids have been constructed containing the full length cDNA for oTF and

chimeric cDNAs for hTF/2N-oTF/2C and oTF/2N-hTF/2C.

Characteristics of the site-directed mutants include: the D63S mutant does bind iron (contrary to speculations in the literature) but much less avidly than the wild type protein. For instance, this mutant loses its bound iron on electrophoresis in PAGE gels containing 8 M urea, whereas the wild type retains its bound iron. The maximum in the visible spectrum lies at 422 nm in contrast to that of the wild type at 470 nm. The G65R mutant binds iron less tightly than does the wild type and has a visible maximum at 470 nm. The K206Q mutant binds iron much more avidly than does the wild type, as does its model, oTF/2C. Whereas the red color of the wild type iron protein disappears very rapidly in 0.5 M acetate buffer at pH 4.9, containing 1 mM each of EDTA and NTA, the mutant loses no color at all and requires pH 4 and 1 mM deferoxamine to release its bound iron. The apo-mutant appears to rebind iron more slowly than the wild type protein. The visible maximum lies at 460 nm for this mutant. The H207E mutant also binds iron more avidly than does the wild type.

The full length recombinant hTF runs at the same rate as the serum-derived protein on SDS-PAGE.

V. Removal of Glycosylation Sites from hTf.

Human serum transferrin contains two N-linked oligosaccharides, at Asn-413 and Asn-611 (MacGillivray *et al.* (1982) PNAS USA 79:2504-2508), corresponding to AAT and AAC codons in the cDNA sequence, respectively (Yang *et al.* (1984) Proc. Natl. Acad. Sci. USA 81:2752-2756). These codons were converted to GAT and GAC by oligonucleotide-directed mutagenesis using the dut⁻ and ung⁻ method (Kunkel, T.A. (1985) Proc. Natl. Acad. Sci. USA 82:488-492). The mutagenic oligonucleotides:

5'-GCAGAAACTACGATAAAGAGCGATAAT-3' (SEQ ID NO:3)

5'-CTATTTGGAAGCGACGTAACTGACTGC-3' (SEQ ID NO:4)

(the mutated codons are underlined) were synthesized on an Applied Biosystems 391 DNA synthesizer, and were purified by reverse-phase chromatography using a SEP-PAK (Waters) column (Atkinson, T. and Smith, M. (1984) Oligonucleotide Synthesis: A Practical Approach (Gait, M.J., Ed.) pp 35-81, IRL Press, Oxford).

The template for the mutagenesis was a plasmid containing the DNA coding sequence for the C-lobe of transferrin cloned into pUC named pUC2-3; as shown in Figure 8, this plasmid contains a *NotI* site in the interlobe bridge coding region and a *SmaI* site in both the 5' and 3' untranslated regions. Each of the two mutagenic oligonucleotides was used separately to introduce the desired mutations into pUC2-3; the resulting plasmids

were Tf-N413D and Tf-N611D (see Figure 8). The presence of the mutated codons was confirmed by DNA sequence analysis (Sanger, F. *et al.* (1977) Proc. Natl. Acad. Sci. USA 74:5463-5467). Each plasmid was cut with *AccI* and *StuI*, the DNA fragments were separated by agarose gel electrophoresis, and the fragments containing the mutated
5 residues were recovered from gel slices using GENECLAN (Bio101, La Jolla, CA). The fragments were then ligated back into the *AccI* site of the full-length transferrin cDNA clone in pUC19. The structure of the final construction, hTf(N/D), was confirmed by restriction mapping and DNA sequence analysis. The transferrin cDNA was then released with *SacI* and *SphI*; the ends were made blunt by treatment with the Klenow fragment of
10 DNA polymerase I in the presence of dNTPS and ligated directly into pNUT restricted with *SmaI* (Palmiter, R.D. *et al.* (1987) Cell 50:435-443) as described for the N- and C-terminal transferring half-molecule coding sequences. The correct orientation of the pNUT-hTf(N/D) clone was confirmed by restriction-endonuclease mapping.

The pNUT-hTf (N/D) clone was then treated in the same manner as described for
15 the full recombinant length transferrin. The resulting transformations were selected using 500 μ M MTX.

The isolated hTf N413D/N611D mutant protein was monodisperse on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and had a spectrum and spectral ratios similar to that of serum-derived hTf. However, the hTf N413D/N611D mutant migrates
20 slightly faster than serum-derived hTf.

VI. Cell-Binding Experiments.

HeLa S₃ cells were the generous gift of Dr. Joan Moehring (Department of
25 Microbiology, University of Vermont College of Medicine). Cells were routinely grown in DMEM-F-12 containing 10% newborn calf serum. Prior to beginning a binding experiment, the cells were harvested with Versene, and taken up in Joklik's minimum essential medium-20 mM Hepes-2% BSA (JMEM-BSA). Endogenous bovine transferrin was removed from the HeLa cells by incubation for 10 min at 37°C at a 5-fold dilution
30 with JMEM-BSA. After centrifugation of the cells and removal of the supernatant, this procedure was repeated twice. The cells were then incubated for an additional 10 min in the presence of 10 mM NH₄Cl to inhibit the removal of iron from transferrin (Morgan (1981) Biochim. Biophys. Acta 642:119-134; Harding & Stahl (1983) Biochem. Biophys. Res. Comm. 113:650-658; Rao *et al.* (1983) FEBS Lett. 160:213-216; Klausner, *et al.* (1983) J. Biol. Chem. 257:4715-4724; Mason *et al.* (1987) Biochem J. 245:103-109).
35 Removal of the endogenous transferrin is somewhat superfluous since bovine transferrin has a very low affinity for human receptors and would not effectively compete with human transferrin in the binding studies (Penhallow, R.C. *et al.* (1986) J. Cell. Physiol. 128:251-260). For each diferric hTf sample to be tested, cell suspensions (300 μ L

containing $\sim 2.2 \times 10^6$ cells) were added to eight different Omnivials containing between 3 and 80 pmol of radiolabeled diferric transferrin. An identical set of vials was set up containing a 100-fold excess of unlabeled Boehringer Mannheim diferric transferrin to determine the amount of nonspecific binding. After 30 min of incubation at 37°C with gentle shaking, portions of the cell suspension ($3 \times 100 \mu\text{L}$) were pipetted into microfuge tubes containing 0.9 mL of ice-cold JMEM-BSA over 300 μL of dibutyl phthalate and centrifuged for 2 min in a Beckman microfuge. The aqueous and organic phases were aspirated to just above the cell pellet. The bottom of the tube containing the cell pellet was released by a hot wire into a plastic tube (12 x 75 mm) and assayed for radioactivity. A second approach involved competing six different amounts (4-120 pmol) of each of the different hTf samples against a constant amount (6.4 pmol) of radioiodinated Boehringer Mannheim hTf. The program LIGAND was used to analyze the data from both types of experiment assuming a single class of binding sites in each case (Munson & Rodbard, (1980) Anal. Biochem. 107:220-239).

In order to test the functional integrity of the five different hTf samples, equilibrium binding studies were undertaken using two different approaches as discussed above. First, each hTf sample was radioiodinated, and direct binding to HeLa S₃ cells was measured in the presence and absence of a 100-fold excess of unlabeled Boehringer Mannheim Fe₂hTf. In all instances, the amount of nonspecific binding was very low, less than 5% of the specific binding. The data from the equilibrium binding experiment were analyzed by the nonlinear curve-fitting program of Munson and Rodbard to determine the affinity and binding site number for each TF (Munson & Rodbard, (1980) Anal. Biochem. 107:220-239). A typical data set is presented in Table 2. The results show that all of the transferrins bound with approximately the same affinity and to the same extent.

The second approach involved competing different amounts of each of the transferrins (unlabeled) against a constant amount of radioiodinated Boehringer Mannheim diferric hTf. The results of a typical data set from this approach are presented in Table IIIB. The two experiments shown were done on different days which probably accounts for the difference in the number of binding sites per cell observed. In many experiments over a number of years (Penhallow, R.C. *et al.* (1986) J. Cell. Physiol. 128:251-260), between 0.8 and 2×10^6 sites/cell have been found, which probably reflects the metabolic state of the cells. Binding of the recombinant Tf samples is indistinguishable from binding of the commercially available Tf samples.

Table 2^a

transferrin	K _d ^b (nM)	TF/cell ^c x 10 ⁻⁶	N ^d
(A) Results of Equilibrium Binding Experiments in which Binding of Radioiodinated Diferric Transferrin to HeLa S ₃ Cells Was Directly Measured			
recombinant glycosylated	31.3 ± 3.6	2.09 ± 0.14	0.004 ± 0.003
recombinant nonglycosylated	23.4 ± 2.5	1.96 ± 0.13	0.013 ± 0.003
Boehringer Mannheim	17.8 ± 2.3	1.31 ± 0.08	0.019 ± 0.003
Sigma	19.9 ± 1.5	1.76 ± 0.14	0.009 ± 0.004
Scipac	22.5 ± 2.9	1.76 ± 0.09	0.008 ± 0.002
(B) Results of Equilibrium Binding Experiments in which Six Different Amounts of Unlabeled Transferrin Were Competed against a Constant Amount of Boehringer Mannheim Radioiodinated Transferrin			
recombinant glycosylated	22.6 ± 2.4	0.99 ± 0.03	0
recombinant nonglycosylated	19.8 ± 7.4	0.91 ± 0.07	0
Boehringer Mannheim	29.7 ± 1.6	1.00 ± 0.10	0.015 ± 0.006
Sigma	19.6 ± 9.7	0.79 ± 0.07	0.018 ± 0.005
Scipac	30.0 ± 1.8	1.04 ± 0.10	0.013 ± 0.006

^aIn (A), 7482 cpm bound (3.28 x 10⁵ TF/cell) in the absence of competitor. A total of 44 cpm bound in the presence of 100-fold excess of unlabeled competitor. ^bIn both experiments, K_d' denotes the apparent equilibrium binding constant. ^cTF/cell denotes the number of TF molecules bound per cell. ^dN denotes the ratio of nonspecifically bound to free transferrin.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: FUNK, Walter D.
MacGILLIVRAY, Ross T.A.
MASON, Anne B.
WOODWORTH, Robert C.

(ii) TITLE OF INVENTION: RECOMBINANT TRANSFERRINS, TRANSFERRIN HALF-
MOLECULES AND MUTANTS THEREOF

(iii) NUMBER OF SEQUENCES: 7

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: LAHIVE & COCKFIELD
(B) STREET: 60 State Street, suite 510
(C) CITY: Boston
(D) STATE: Massachusetts
(E) COUNTRY: USA
(F) ZIP: 02109

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII text

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE: 28-DEC-1993
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 07/832,029
(B) FILING DATE: 06-FEB-1992
(C) CLASSIFICATION: 1814

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: DeConti, Giulio A.
(B) REGISTRATION NUMBER: 31,503
(C) REFERENCE/DOCKET NUMBER: UVI-005CP2

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617) 227-7400
(B) TELEFAX: (617) 227-5941

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2327 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 31..2124

5

(ix) FEATURE:

(A) NAME/KEY: mat_peptide

(B) LOCATION: 88..2124

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

	TGTGCTCGCT GCTCAGCGCG CACCCGGAAG ATG AGG CTC GCC GTG GGA GCC CTG	54
	Met Arg Leu Ala Val Gly Ala Leu	
15	-19 -15	
	CTG GTC TGC GCC GTC CTG GGG CTG TGT CTG GCT GTC CCT GAT AAA ACT	102
	Leu Val Cys Ala Val Leu Gly Leu Cys Leu Ala Val Pro Asp Lys Thr	
	-10 -5 1 5	
20	GTG AGA TGG TGT GCA GTG TCG GAG CAT GAG GCC ACT AAG TGC CAG AGT	150
	Val Arg Trp Cys Ala Val Ser Glu His Glu Ala Thr Lys Cys Gln Ser	
	10 15 20	
25	TTC CGC GAC CAT ATG AAA AGC GTC ATT CCA TCC GAT GGT CCC AGT GTT	198
	Phe Arg Asp His Met Lys Ser Val Ile Pro Ser Asp Gly Pro Ser Val	
	25 30 35	
30	GCT TGT GTG AAG AAA GCC TCC TAC CTT GAT TGC ATC AGG GCC ATT GCG	246
	Ala Cys Val Lys Lys Ala Ser Tyr Leu Asp Cys Ile Arg Ala Ile Ala	
	40 45 50	
35	GCA AAC GAA GCG GAT GCT GTG ACA CTG GAT GCA GGT TTG GTC TAT GAT	294
	Ala Asn Glu Ala Asp Ala Val Thr Leu Asp Ala Gly Leu Val Tyr Asp	
	55 60 65	
40	GCT TAC TTG GCT CCC AAT AAC CTG AAG CCT GTG GTG GCA GAG TTC TAT	342
	Ala Tyr Leu Ala Pro Asn Asn Leu Lys Pro Val Val Ala Glu Phe Tyr	
	70 75 80 85	
45	GGG TCA AAA GAG GAT CCA CAG ACT TTC TAT TAT GCT GTT GCT GTG GTG	390
	Gly Ser Lys Glu Asp Pro Gln Thr Phe Tyr Tyr Ala Val Ala Val Val	
	90 95 100	
50	AAG AAG GAT AGT GGC TTC CAG ATG AAC CAG CTT CGA GGC AAG AAG TCC	438
	Lys Lys Asp Ser Gly Phe Gln Met Asn Gln Leu Arg Gly Lys Lys Ser	
	105 110 115	
55	TGC CAC ACG GGT CTA GGC AGG TCC GCT GGG TGG AAC ATC CCC ATA GGC	486
	Cys His Thr Gly Leu Gly Arg Ser Ala Gly Trp Asn Ile Pro Ile Gly	
	120 125 130	
	TTA CTT TAC TGT GAC TTA CCT GAG CCA CGT AAA CCT CTT GAG AAA GCA	534
	Leu Leu Tyr Cys Asp Leu Pro Glu Pro Arg Lys Pro Leu Glu Lys Ala	
	135 140 145	
	GTG GCC AAT TTC TTC TCG GGC AGC TGT GCC CCT TGT GCG GAT GGG ACC	582
	Val Ala Asn Phe Phe Ser Gly Ser Cys Ala Pro Cys Ala Asp Gly Thr	
	150 155 160 165	

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

	GAC	TTC	CCC	CAG	CTG	TGT	CAA	CTG	TGT	CCA	GGG	TGT	GGC	TGC	TCC	ACC	630
	Asp	Phe	Pro	Gln	Leu	Cys	Gln	Leu	Cys	Pro	Gly	Cys	Gly	Cys	Ser	Thr	
					170					175						180	
5	CTT	AAC	CAA	TAC	TTC	GGC	TAC	TCG	GGA	GCC	TTC	AAG	TGT	CTG	AAG	GAT	678
	Leu	Asn	Gln	Tyr	Phe	Gly	Tyr	Ser	Gly	Ala	Phe	Lys	Cys	Leu	Lys	Asp	
				185					190					195			
10	GGT	GCT	GGG	GAT	GTG	GCC	TTT	GTC	AAG	CAC	TCG	ACT	ATA	TTT	GAG	AAC	726
	Gly	Ala	Gly	Asp	Val	Ala	Phe	Val	Lys	His	Ser	Thr	Ile	Phe	Glu	Asn	
			200					205					210				
15	TTG	GCA	AAC	AAG	GCT	GAC	AGG	GAC	CAG	TAT	GAG	CTG	CTT	TGC	CTA	GAC	774
	Leu	Ala	Asn	Lys	Ala	Asp	Arg	Asp	Gln	Tyr	Glu	Leu	Leu	Cys	Leu	Asp	
		215					220					225					
20	AAC	ACC	CGG	AAG	CCG	GTA	GAT	GAA	TAC	AAG	GAC	TGC	CAC	TTG	GCC	CAG	822
	Asn	Thr	Arg	Lys	Pro	Val	Asp	Glu	Tyr	Lys	Asp	Cys	His	Leu	Ala	Gln	
	230					235					240					245	
25	GTC	CCT	TCT	CAT	ACC	GTC	GTG	GCC	CGA	AGT	ATG	GGC	GGC	AAG	GAG	GAC	870
	Val	Pro	Ser	His	Thr	Val	Val	Ala	Arg	Ser	Met	Gly	Gly	Lys	Glu	Asp	
					250					255					260		
30	TTG	ATC	TGG	GAG	CTT	CTC	AAC	CAG	GCC	CAG	GAA	CAT	TTT	GGC	AAA	GAC	918
	Leu	Ile	Trp	Glu	Leu	Leu	Asn	Gln	Ala	Gln	Glu	His	Phe	Gly	Lys	Asp	
			265					270					275				
35	AAA	TCA	AAA	GAA	TTC	CAA	CTA	TTC	AGC	TCT	CCT	CAT	GGG	AAG	GAC	CTG	966
	Lys	Ser	Lys	Glu	Phe	Gln	Leu	Phe	Ser	Ser	Pro	His	Gly	Lys	Asp	Leu	
			280					285					290				
40	CTG	TTT	AAG	GAC	TCT	GCC	CAC	GGG	TTT	TTA	AAA	GTC	CCC	CCA	AGG	ATG	1014
	Leu	Phe	Lys	Asp	Ser	Ala	His	Gly	Phe	Leu	Lys	Val	Pro	Pro	Arg	Met	
		295					300					305					
45	GAT	GCC	AAG	ATG	TAC	CTG	GGC	TAT	GAG	TAT	GTC	ACT	GCC	ATC	CGG	AAT	1062
	Asp	Ala	Lys	Met	Tyr	Leu	Gly	Tyr	Glu	Tyr	Val	Thr	Ala	Ile	Arg	Asn	
	310					315					320					325	
50	CTA	CGG	GAA	GGC	ACA	TGC	CCA	GAA	GCC	CCA	ACA	GAT	GAA	TGC	AAG	CCT	1110
	Leu	Arg	Glu	Gly	Thr	Cys	Pro	Glu	Ala	Pro	Thr	Asp	Glu	Cys	Lys	Pro	
					330					335					340		
55	GTG	AAG	TGG	TGT	GCG	CTG	AGC	CAC	CAC	GAG	AGG	CTC	AAG	TGT	GAT	GAG	1158
	Val	Lys	Trp	Cys	Ala	Leu	Ser	His	His	Glu	Arg	Leu	Lys	Cys	Asp	Glu	
				345				350						355			
60	TGG	AGT	GTT	AAC	AGT	GTA	GGG	AAA	ATA	GAG	TGT	GTA	TCA	GCA	GAG	ACC	1206
	Trp	Ser	Val	Asn	Ser	Val	Gly	Lys	Ile	Glu	Cys	Val	Ser	Ala	Glu	Thr	
			360					365					370				
65	ACC	GAA	GAC	TGC	ATC	GCC	AAG	ATC	ATG	AAT	GGA	GAA	GCT	GAT	GCC	ATG	1254
	Thr	Glu	Asp	Cys	Ile	Ala	Lys	Ile	Met	Asn	Gly	Glu	Ala	Asp	Ala	Met	
		375					380					385					

	AGC	TTG	GAT	GGA	GGG	TTT	GTC	TAC	ATA	GCG	GGC	AAG	TGT	GGT	CTG	GTG	1302
	Ser	Leu	Asp	Gly	Gly	Phe	Val	Tyr	Ile	Ala	Gly	Lys	Cys	Gly	Leu	Val	
	390					395					400					405	
5	CCT	GTC	TTG	GCA	GAA	AAC	TAC	AAT	AAG	AGC	GAT	AAT	TGT	GAG	GAT	ACA	1350
	Pro	Val	Leu	Ala	Glu	Asn	Tyr	Asn	Lys	Ser	Asp	Asn	Cys	Glu	Asp	Thr	
					410					415					420		
10	CCA	GAG	GCA	GGG	TAT	TTT	GCT	GTA	GCA	GTG	GTG	AAG	AAA	TCA	GCT	TCT	1398
	Pro	Glu	Ala	Gly	Tyr	Phe	Ala	Val	Ala	Val	Val	Lys	Lys	Ser	Ala	Ser	
				425					430					435			
15	GAC	CTC	ACC	TGG	GAC	AAT	CTG	AAA	GGC	AAG	AAG	TCC	TGC	CAT	ACG	GCA	1446
	Asp	Leu	Thr	Trp	Asp	Asn	Leu	Lys	Gly	Lys	Lys	Ser	Cys	His	Thr	Ala	
			440					445					450				
20	GTT	GGC	AGA	ACC	GCT	GGC	TGG	AAC	ATC	CCC	ATG	GGC	CTG	CTC	TAC	AAT	1494
	Val	Gly	Arg	Thr	Ala	Gly	Trp	Asn	Ile	Pro	Met	Gly	Leu	Leu	Tyr	Asn	
		455					460					465					
25	AAG	ATC	AAC	CAC	TGC	AGA	TTT	GAT	GAA	TTT	TTC	AGT	GAA	GGT	TGT	GCC	1542
	Lys	Ile	Asn	His	Cys	Arg	Phe	Asp	Glu	Phe	Phe	Ser	Glu	Gly	Cys	Ala	
	470					475					480					485	
30	CCT	GGG	TCT	AAG	AAA	GAC	TCC	AGT	CTC	TGT	AAG	CTG	TGT	ATG	GGC	TCA	1590
	Pro	Gly	Ser	Lys	Lys	Asp	Ser	Ser	Leu	Cys	Lys	Leu	Cys	Met	Gly	Ser	
					490					495					500		
35	GGC	CTA	AAC	CTG	TGT	GAA	CCC	AAC	AAC	AAA	GAG	GGA	TAC	TAC	GGC	TAC	1638
	Gly	Leu	Asn	Leu	Cys	Glu	Pro	Asn	Asn	Lys	Glu	Gly	Tyr	Tyr	Gly	Tyr	
				505					510					515			
40	ACA	GGC	GCT	TTC	AGG	TGT	CTG	GTT	GAG	AAG	GGA	GAT	GTG	GCC	TTT	GTG	1686
	Thr	Gly	Ala	Phe	Arg	Cys	Leu	Val	Glu	Lys	Gly	Asp	Val	Ala	Phe	Val	
			520					525					530				
45	AAA	CAC	CAG	ACT	GTC	CCA	CAG	AAC	ACT	GGG	GGA	AAA	AAC	CCT	GAT	CCA	1734
	Lys	His	Gln	Thr	Val	Pro	Gln	Asn	Thr	Gly	Gly	Lys	Asn	Pro	Asp	Pro	
		535					540					545					
50	TGG	GCT	AAG	AAT	CTG	AAT	GAA	AAA	GAC	TAT	GAG	TTG	CTG	TGC	CTT	GAT	1782
	Trp	Ala	Lys	Asn	Leu	Asn	Glu	Lys	Asp	Tyr	Glu	Leu	Leu	Cys	Leu	Asp	
	550					555					560					565	
55	GGT	ACC	AGG	AAA	CCT	GTG	GAG	GAG	TAT	GCG	AAC	TGC	CAC	CTG	GCC	AGA	1830
	Gly	Thr	Arg	Lys	Pro	Val	Glu	Glu	Tyr	Ala	Asn	Cys	His	Leu	Ala	Arg	
					570					575					580		
60	GCC	CCG	AAT	CAC	GCT	GTG	GTC	ACA	CGG	AAA	GAT	AAG	GAA	GCT	TGC	GTC	1878
	Ala	Pro	Asn	His	Ala	Val	Val	Thr	Arg	Lys	Asp	Lys	Glu	Ala	Cys	Val	
				585					590					595			
65	CAC	AAG	ATA	TTA	CGT	CAA	CAG	CAG	CAC	CTA	TTT	GGA	AGC	AAC	GTA	ACT	1926
	His	Lys	Ile	Leu	Arg	Gln	Gln	Gln	His	Leu	Phe	Gly	Ser	Asn	Val	Thr	
			600					605					610				
70	GAC	TGC	TCG	GGC	AAC	TTT	TGT	TTG	TTC	CGG	TCG	GAA	ACC	AAG	GAC	CTT	1974
	Asp	Cys	Ser	Gly	Asn	Phe	Cys	Leu	Phe	Arg	Ser	Glu	Thr	Lys	Asp	Leu	
		615					620						625				

CTG TTC AGA GAT GAC ACA GTA TGT TTG GCC AAA CTT CAT GAC AGA AAC 2022
 Leu Phe Arg Asp Asp Thr Val Cys Leu Ala Lys Leu His Asp Arg Asn
 630 635 640 645

5 ACA TAT GAA AAA TAC TTA GGA GAA GAA TAT GTC AAG GCT GTT GGT AAC 2070
 Thr Tyr Glu Lys Tyr Leu Gly Glu Glu Tyr Val Lys Ala Val Gly Asn
 650 655 660

10 CTG AGA AAA TGC TCC ACC TCA TCA CTC CTG GAA GCC TGC ACT TTC CGT 2118
 Leu Arg Lys Cys Ser Thr Ser Ser Leu Leu Glu Ala Cys Thr Phe Arg
 665 670 675

15 AGA CCT TAAATCTCA GAGGTAGGGC TGCCACCAAG GTGAAGATGG GAACGCAGAT 2174
 Arg Pro

GATCCATGAG TTTGCCCTGG TTTCCTGGC CCAAGTGGTT TGTGCTAACC ACGTCTGTCT 2234

20 TCACAGCTCT GTGTTGCCAT GTGTGCTGAA CAAAAAATAA AAATTATTAT TGATTTTATA 2294

TTTCAAAAAA AAAAAAAAAA AAAAAAAAAA AAA 2327

25 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 698 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

35 Met Arg Leu Ala Val Gly Ala Leu Leu Val Cys Ala Val Leu Gly Leu
 -19 -15 -10 -5

40 Cys Leu Ala Val Pro Asp Lys Thr Val Arg Trp Cys Ala Val Ser Glu
 1 5 10

His Glu Ala Thr Lys Cys Gln Ser Phe Arg Asp His Met Lys Ser Val
 15 20 25

45 Ile Pro Ser Asp Gly Pro Ser Val Ala Cys Val Lys Lys Ala Ser Tyr
 30 35 40 45

Leu Asp Cys Ile Arg Ala Ile Ala Ala Asn Glu Ala Asp Ala Val Thr
 50 55 60

50 Leu Asp Ala Gly Leu Val Tyr Asp Ala Tyr Leu Ala Pro Asn Asn Leu
 65 70 75

Lys Pro Val Val Ala Glu Phe Tyr Gly Ser Lys Glu Asp Pro Gln Thr
 55 80 85 90

Phe Tyr Tyr Ala Val Ala Val Val Lys Lys Asp Ser Gly Phe Gln Met
 95 100 105

	Asn	Gln	Leu	Arg	Gly	Lys	Lys	Ser	Cys	His	Thr	Gly	Leu	Gly	Arg	Ser	110	115	120	125
5	Ala	Gly	Trp	Asn	Ile	Pro	Ile	Gly	Leu	Leu	Tyr	Cys	Asp	Leu	Pro	Glu	130	135	140	
	Pro	Arg	Lys	Pro	Leu	Glu	Lys	Ala	Val	Ala	Asn	Phe	Phe	Ser	Gly	Ser	145	150	155	
10	Cys	Ala	Pro	Cys	Ala	Asp	Gly	Thr	Asp	Phe	Pro	Gln	Leu	Cys	Gln	Leu	160	165	170	
	Cys	Pro	Gly	Cys	Gly	Cys	Ser	Thr	Leu	Asn	Gln	Tyr	Phe	Gly	Tyr	Ser	175	180	185	
15	Gly	Ala	Phe	Lys	Cys	Leu	Lys	Asp	Gly	Ala	Gly	Asp	Val	Ala	Phe	Val	190	195	200	205
20	Lys	His	Ser	Thr	Ile	Phe	Glu	Asn	Leu	Ala	Asn	Lys	Ala	Asp	Arg	Asp	210	215	220	
	Gln	Tyr	Glu	Leu	Leu	Cys	Leu	Asp	Asn	Thr	Arg	Lys	Pro	Val	Asp	Glu	225	230	235	
25	Tyr	Lys	Asp	Cys	His	Leu	Ala	Gln	Val	Pro	Ser	His	Thr	Val	Val	Ala	240	245	250	
	Arg	Ser	Met	Gly	Gly	Lys	Glu	Asp	Leu	Ile	Trp	Glu	Leu	Leu	Asn	Gln	255	260	265	
30	Ala	Gln	Glu	His	Phe	Gly	Lys	Asp	Lys	Ser	Lys	Glu	Phe	Gln	Leu	Phe	270	275	280	285
	Ser	Ser	Pro	His	Gly	Lys	Asp	Leu	Leu	Phe	Lys	Asp	Ser	Ala	His	Gly	290	295	300	
35	Phe	Leu	Lys	Val	Pro	Pro	Arg	Met	Asp	Ala	Lys	Met	Tyr	Leu	Gly	Tyr	305	310	315	
40	Glu	Tyr	Val	Thr	Ala	Ile	Arg	Asn	Leu	Arg	Glu	Gly	Thr	Cys	Pro	Glu	320	325	330	
	Ala	Pro	Thr	Asp	Glu	Cys	Lys	Pro	Val	Lys	Trp	Cys	Ala	Leu	Ser	His	335	340	345	
45	His	Glu	Arg	Leu	Lys	Cys	Asp	Glu	Trp	Ser	Val	Asn	Ser	Val	Gly	Lys	350	355	360	365
	Ile	Glu	Cys	Val	Ser	Ala	Glu	Thr	Thr	Glu	Asp	Cys	Ile	Ala	Lys	Ile	370	375	380	
50	Met	Asn	Gly	Glu	Ala	Asp	Ala	Met	Ser	Leu	Asp	Gly	Gly	Phe	Val	Tyr	385	390	395	
	Ile	Ala	Gly	Lys	Cys	Gly	Leu	Val	Pro	Val	Leu	Ala	Glu	Asn	Tyr	Asn	400	405	410	
55	Lys	Ser	Asp	Asn	Cys	Glu	Asp	Thr	Pro	Glu	Ala	Gly	Tyr	Phe	Ala	Val	415	420	425	

Ala Val Val Lys Lys Ser Ala Ser Asp Leu Thr Trp Asp Asn Leu Lys
430 435 440 445

5 Gly Lys Lys Ser Cys His Thr Ala Val Gly Arg Thr Ala Gly Trp Asn
450 455 460

Ile Pro Met Gly Leu Leu Tyr Asn Lys Ile Asn His Cys Arg Phe Asp
465 470 475

10 Glu Phe Phe Ser Glu Gly Cys Ala Pro Gly Ser Lys Lys Asp Ser Ser
480 485 490

15 Leu Cys Lys Leu Cys Met Gly Ser Gly Leu Asn Leu Cys Glu Pro Asn
495 500 505

Asn Lys Glu Gly Tyr Tyr Gly Tyr Thr Gly Ala Phe Arg Cys Leu Val
510 515 520 525

20 Glu Lys Gly Asp Val Ala Phe Val Lys His Gln Thr Val Pro Gln Asn
530 535 540

Thr Gly Gly Lys Asn Pro Asp Pro Trp Ala Lys Asn Leu Asn Glu Lys
545 550 555

25 Asp Tyr Glu Leu Leu Cys Leu Asp Gly Thr Arg Lys Pro Val Glu Glu
560 565 570

Tyr Ala Asn Cys His Leu Ala Arg Ala Pro Asn His Ala Val Val Thr
575 580 585

Arg Lys Asp Lys Glu Ala Cys Val His Lys Ile Leu Arg Gln Gln Gln
590 595 600 605

35 His Leu Phe Gly Ser Asn Val Thr Asp Cys Ser Gly Asn Phe Cys Leu
610 615 620

Phe Arg Ser Glu Thr Lys Asp Leu Leu Phe Arg Asp Asp Thr Val Cys
625 630 635

40 Leu Ala Lys Leu His Asp Arg Asn Thr Tyr Glu Lys Tyr Leu Gly Glu
640 645 650

Glu Tyr Val Lys Ala Val Gly Asn Leu Arg Lys Cys Ser Thr Ser Ser
655 660 665

Leu Leu Glu Ala Cys Thr Phe Arg Arg Pro
670 675

50 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

5 GCAGAAACT ACGATAAGAG CGATAAT

27

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

20 CTATTTGGAA GCGACGTAAC TGACTGC

27

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Val Pro Asp Lys Thr Val Arg Trp Cys Ala Val Ser
1 5 10

40 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

50 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

55 Val Pro Asp Lys Thr Val Arg Trp Xaa Ala Val Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Val Pro Asp Lys Thr Val

1 5

Claims

1. An essentially homogenous preparation of metal-binding human transferrin free of other human proteins.

5

2. The essentially homogenous preparation of metal-binding human transferrin of claim 1, wherein the human transferrin binds to a transferrin receptor.

3. An essentially homogenous preparation of iron-binding human serum transferrin free of other human serum proteins.

10

4. The essentially homogenous preparation of iron-binding human transferrin of claim 3, wherein the human transferrin binds to a transferrin receptor.

5. Human serum transferrin which binds a metal, essentially free of other serum proteins, produced by:

15

- a) culturing a eukaryotic cell transfected with an expression vector of claim 14 under conditions conducive to expression of the transferrin; and
- b) recovering the expressed transferrin.

20

6. A mutant human serum transferrin half-molecule comprising at least the metal-binding domain of a single lobe of transferrin, but not the metal-binding domain of the other lobe, the mutant having a stronger binding avidity for metal than the binding avidity of natural human serum transferrin.

25

7. A mutant transferrin half-molecule of claim 6, which has a stronger binding avidity for iron than natural human serum transferrin.

8. A mutant transferrin half-molecule of claim 7, comprising at least the metal-binding domain of a single lobe of transferrin wherein the lysine residue at position 206 of natural human serum transferrin is replaced with glutamine.

5 9. A mutant transferrin half-molecule of claim 7, comprising at least the metal-binding domain of a single lobe of transferrin wherein the lysine residue at position 206 of the amino acid sequence of natural human serum transferrin shown in SEQ ID NO:2 is replaced with glutamine.

10 10. A mutant transferrin half-molecule of claim 7, comprising at least the metal-binding domain of a single lobe of transferrin wherein the histidine residue at position 207 of natural human serum transferrin is replaced with glutamic acid.

11. A mutant transferrin half-molecule of claim 7, comprising at least the metal-binding
15 domain of a single lobe of transferrin wherein the histidine residue at position 207 of the amino acid sequence of natural human serum transferrin shown in SEQ ID NO:2 is replaced with glutamic acid.

12. An essentially homogenous preparation of non-glycosylated metal-binding human
20 transferrin free of other human proteins.

13. The essentially homogenous preparation of non-glycosylated metal-binding human transferrin of claim 12, wherein the metal is iron.

25 14. An eukaryotic expression vector, comprising a nucleic acid construct comprising nucleic acid encoding a transferrin or a transferrin half-molecule comprising at least the binding domain of a single lobe of transferrin linked to appropriate genetic regulatory elements for expression in an eukaryotic cell.

15. An eukaryotic expression of vector of claim 14, wherein the nucleic acid construct includes a nucleic acid encoding transferrin signal sequence linked to the nucleic acid encoding the transferrin or transferrin half-molecule.

5 16. An eukaryotic expression vector of claim 15, wherein the single lobe is the amino terminal lobe of human serum transferrin.

17. An eukaryotic expression vector of claim 15, wherein the single lobe is the carboxy terminal lobe of human serum transferrin.

10

18. An eukaryotic expression vector of claim 14, wherein the transferrin half-molecule contains a glutamine residue at position 206 in place of the lysine residue of natural transferrin.

15 19. An eukaryotic cell line transfected with the vector of claim 14.

20. A baby hamster kidney cell line transfected with the vector of claim 14.

21. A method of producing functionally active human transferrin, comprising:

- 20 a) culturing a eukaryotic cell transfected with an expression vector containing DNA encoding the transferrin, under conditions conducive to expression of transferrin; and
- b) recovering the expressed transferrin.

25 22. A method of claim 21, wherein the vector is the plasmid pNUT.

23. A method of claim 21, wherein the eukaryotic cell is a baby hamster kidney cell.

24. A method of producing a functionally active human serum transferrin, comprising:
- a) culturing a eukaryotic cell transfected with an expression vector comprising DNA encoding human serum transferrin, or a portion thereof, operably linked to an inducible promoter of transferrin;
 - b) inducing the promoter in order to induce expression of transferrin; and
 - c) recovering the expressed transferrin.

25. A method of claim 24, wherein the promoter is the zinc inducible metallothionein promoter.

26. A nonserum supplement for cell culture medium containing human serum ransferrin produced by a method of claim 24.

RECOMBINANT TRANSFERRINS, TRANSFERRIN HALF-MOLECULES AND MUTANTS THEREOF

Recombinant transferrin, non-glycosylated recombinant transferrin,
5 transferrin half-molecules and mutant transferrins having altered metal-binding or other
properties are described. The recombinant transferrin molecules are expressed in
functional form by stable eukaryotic cell lines such as baby hamster kidney cells
transformed with an expression vector encoding the recombinant molecule. The
recombinant transferrins can be used in metal chelation therapy to bind and clear excess
10 toxic metals in patients suffering from metal overloads or as tissue culture medium
supplements or replacements.




FIGURE 1




FIGURE 2

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted May 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.





FIGURE 3

FIGURE 5

00426240 1150




FIGURE 6




FIGURE 7




FIGURE 8

Attorney's
Docket
Number UVI-005CP2

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Recombinant Transferrins, Transferrin Half-Molecules and Mutants Thereof
the specification of which

(check one)

☐ is attached hereto.

☒ was filed on December 28, 1993 as

Application Serial No. 08/175,158

and was amended on _____
(if applicable)

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one:

☒ no such applications have been filed.

☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

<u>832,029</u> (Application Serial No.)	<u>February 6, 1992</u> (Filing Date)	<u>Pending</u> (Status) (patented,pending,aband.)
<u>652,869</u> (Application Serial No.)	<u>February 8, 1991</u> (Filing Date)	<u>Abandoned</u> (Status) (patented,pending,aband.)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John A. Lahive, Jr.	Reg. No. 19,788	Michael I. Falkoff	Reg. No. 30,833
W. Hugo Liepmann	Reg. No. 20,407	Ann Lamport Hammitte	Reg. No. 34,858
James E. Cockfield	Reg. No. 19,162	John V. Bianco	Reg. No. 36,748
Thomas V. Smurzynski	Reg. No. 24,798	Jeremiah Lynch	Reg. No. 17,425
Ralph A. Loren	Reg. No. 29,325	Amy E. Mandragouras	Reg. No. 36,207
Thomas J. Engellenner	Reg. No. 28,711	Elizabeth A. Hanley	Reg. No. 33,505
William C. Geary III	Reg. No. 31,359	Matthew P. Vincent	Reg. No. 36,709
David J. Powsner	Reg. No. 31,868	Paul Louis Myers	Reg. No. 35,965
Giulio A. DeConti, Jr.	Reg. No. 31,503	Elizabeth A. Levy	Reg. No. 34,375

Send Correspondence to:

Giulio A. DeConti, Jr., Esq., Lahive & Cockfield, 60 State Street, Boston, MA 02109


Direct Telephone Calls to: (name and telephone number)

Giulio A. DeConti, Jr., Esq., (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Walter D. Funk	
Inventor's signature	Date
Residence 11991 Audelia Road, Apt. 2202, Dallas, TX 75243	
Citizenship Canada	
Post Office Address (if different)	

Full name of second inventor, if any Ross T.A. MacGillivray	
Inventor's signature 	Date Feb 14/94
Residence Apt. 807, 2233 Allison Road, Vancouver, British Columbia V6T 1T7 Canada	
Citizenship United Kingdom	
Post Office Address (if different)	

Full name of third inventor, if any Anne B. Mason	
Inventor's signature	Date
Residence North Greenbush Road, Charlotte, VT 05445	
Citizenship United States	
Post Office Address (if different)	

Full name of fourth inventor, if any Robert C. Woodworth	
Inventor's signature	Date
Residence 4 Logan Lane, Shelburne, VT 05482	
Citizenship United States	
Post Office Address (if different)	

Attorney's
Docket
Number UVI-005CP2

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Recombinant Transferrins, Transferrin Half-Molecules and Mutants Thereof
the specification of which

(check one)

 is attached hereto.

X was filed on December 28, 1993 as

Application Serial No. 08/175,158

and was amended on _____
(if applicable)

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one:

☒ no such applications have been filed.

☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			_ Yes No _
			_ Yes No _
			_ Yes No _
			_ Yes No _
			_ Yes No _

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

832,029
(Application Serial No.)

February 6, 1992
(Filing Date)

Pending
(Status)
(patented,pending,aband.)

652,869
(Application Serial No.)

February 8, 1991
(Filing Date)

Abandoned
(Status)
(patented,pending,aband.)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John A. Lahive, Jr.	Reg. No. 19,788	Michael I. Falkoff	Reg. No. 30,833
W. Hugo Liepmann	Reg. No. 20,407	Ann Lamport Hammitte	Reg. No. 34,858
James E. Cockfield	Reg. No. 19,162	John V. Bianco	Reg. No. 36,748
Thomas V. Smurzynski	Reg. No. 24,798	Jeremiah Lynch	Reg. No. 17,425
Ralph A. Loren	Reg. No. 29,325	Amy E. Mandragouras	Reg. No. 36,207
Thomas J. Engellenner	Reg. No. 28,711	Elizabeth A. Hanley	Reg. No. 33,505
William C. Geary III	Reg. No. 31,359	Matthew P. Vincent	Reg. No. 36,709
David J. Powsner	Reg. No. 31,868	Paul Louis Myers	Reg. No. 35,965
Giulio A. DeConti, Jr.	Reg. No. 31,503	Elizabeth A. Levy	Reg. No. 34,375

Send Correspondence to:


Giulio A. DeConti, Jr., Esq., Lahive & Cockfield, 60 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Giulio A. DeConti, Jr., Esq., (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	
Walter D. Funk	
Inventor's signature	Date
	2-8-94
Residence	
11991 Audelia Road, Apt. 2202, Dallas, TX 75243 4858 Mendota St (W) Union City, CA 94557	
Citizenship	
Canada	
Post Office Address (if different)	

Full name of second inventor, if any Ross T.A. MacGillivray	
Inventor's signature	Date
Residence Apt. 807, 2233 Allison Road, Vancouver, British Columbia V6T 1T7 Canada	
Citizenship United Kingdom	
Post Office Address (if different)	

Full name of third inventor, if any Anne B. Mason	
Inventor's signature	Date
Residence North Greenbush Road, Charlotte, VT 05445	
Citizenship United States	
Post Office Address (if different)	

Full name of fourth inventor, if any Robert C. Woodworth	
Inventor's signature	Date
Residence 4 Logan Lane, Shelburne, VT 05482	
Citizenship United States	
Post Office Address (if different)	

Attorney's
Docket
Number UVI-005CP2

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Recombinant Transferrins, Transferrin Half-Molecules and Mutants Thereof
the specification of which

(check one)

 is attached hereto.

X was filed on December 28, 1993 as

Application Serial No. 08/175,158

and was amended on _____
(if applicable)

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one:

☒ no such applications have been filed.

☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

<u>832,029</u> (Application Serial No.)	<u>February 6, 1992</u> (Filing Date)	<u>Pending</u> (Status) (patented,pending,aband.)
<u>652,869</u> (Application Serial No.)	<u>February 8, 1991</u> (Filing Date)	<u>Abandoned</u> (Status) (patented,pending,aband.)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John A. Lahive, Jr.	Reg. No. 19,788	Michael I. Falkoff	Reg. No. 30,833
W. Hugo Liepmann	Reg. No. 20,407	Ann Lamport Hammitte	Reg. No. 34,858
James E. Cockfield	Reg. No. 19,162	John V. Bianco	Reg. No. 36,748
Thomas V. Smurzynski	Reg. No. 24,798	Jeremiah Lynch	Reg. No. 17,425
Ralph A. Loren	Reg. No. 29,325	Amy E. Mandragouras	Reg. No. 36,207
Thomas J. Engellenner	Reg. No. 28,711	Elizabeth A. Hanley	Reg. No. 33,505
William C. Geary III	Reg. No. 31,359	Matthew P. Vincent	Reg. No. 36,709
David J. Powsner	Reg. No. 31,868	Paul Louis Myers	Reg. No. 35,965
Giulio A. DeConti, Jr.	Reg. No. 31,503	Elizabeth A. Levy	Reg. No. 34,375

Send Correspondence to:

Giulio A. DeConti, Jr., Esq., Lahive & Cockfield, 60 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Giulio A. DeConti, Jr., Esq., (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Walter D. Funk	
Inventor's signature	Date
Residence 11991 Audelia Road, Apt. 2202, Dallas, TX 75243	
Citizenship Canada	
Post Office Address (if different)	

Full name of second inventor, if any Ross T.A. MacGillivray	
Inventor's signature	Date
Residence Apt. 807, 2233 Allison Road, Vancouver, British Columbia V6T 1T7 Canada	
Citizenship United Kingdom	
Post Office Address (if different)	

Full name of third inventor, if any Anne B. Mason	
Inventor's signature <i>Anne B. Mason</i>	Date 2/9/94
Residence North Greenbush Road, Charlotte, VT 05445	
Citizenship United States	
Post Office Address (if different)	

Full name of fourth inventor, if any Robert C. Woodworth	
Inventor's signature <i>Robert C. Woodworth</i>	Date 2/9/94
Residence 4 Logan Lane, Shelburne, VT 05482	
Citizenship United States	
Post Office Address (if different)	